Tags

Type your tag names separated by a space and hit enter

A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome.
Am J Cardiol 2008; 102(12A):19L-27LAJ

Abstract

Current treatment guidelines recommend lowering elevated low-density lipoprotein (LDL) cholesterol levels with a statin as the primary lipid-modifying intervention to reduce cardiovascular risk in patients with type 2 diabetes mellitus or metabolic syndrome. However, even with high-dose statin therapy or the combination of statin plus ezetimibe, many patients remain at substantial risk of a cardiovascular event. Increasingly, there is recognition of the importance of treating all components of the atherogenic dyslipidemic profile associated with both conditions, specifically low high-density lipoprotein cholesterol and elevated triglyceride levels, in addition to lowering LDL cholesterol. Both niacin (nicotinic acid) and fibrates are recommended as options for combination with a statin in this setting. Data from ongoing prospective outcomes studies are needed to evaluate the efficacy and safety of these combinations.

Authors+Show Affiliations

Pritzker School of Medicine, University of Chicago, Chicago, Illinois 60610, USA. michaeldavidson@radiantresearch.com

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

19084086

Citation

Davidson, Michael. "A Review of the Current Status of the Management of Mixed Dyslipidemia Associated With Diabetes Mellitus and Metabolic Syndrome." The American Journal of Cardiology, vol. 102, no. 12A, 2008, pp. 19L-27L.
Davidson M. A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. Am J Cardiol. 2008;102(12A):19L-27L.
Davidson, M. (2008). A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. The American Journal of Cardiology, 102(12A), pp. 19L-27L. doi:10.1016/j.amjcard.2008.09.071.
Davidson M. A Review of the Current Status of the Management of Mixed Dyslipidemia Associated With Diabetes Mellitus and Metabolic Syndrome. Am J Cardiol. 2008 Dec 22;102(12A):19L-27L. PubMed PMID: 19084086.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A review of the current status of the management of mixed dyslipidemia associated with diabetes mellitus and metabolic syndrome. A1 - Davidson,Michael, PY - 2008/12/17/entrez PY - 2009/11/7/pubmed PY - 2009/12/16/medline SP - 19L EP - 27L JF - The American journal of cardiology JO - Am. J. Cardiol. VL - 102 IS - 12A N2 - Current treatment guidelines recommend lowering elevated low-density lipoprotein (LDL) cholesterol levels with a statin as the primary lipid-modifying intervention to reduce cardiovascular risk in patients with type 2 diabetes mellitus or metabolic syndrome. However, even with high-dose statin therapy or the combination of statin plus ezetimibe, many patients remain at substantial risk of a cardiovascular event. Increasingly, there is recognition of the importance of treating all components of the atherogenic dyslipidemic profile associated with both conditions, specifically low high-density lipoprotein cholesterol and elevated triglyceride levels, in addition to lowering LDL cholesterol. Both niacin (nicotinic acid) and fibrates are recommended as options for combination with a statin in this setting. Data from ongoing prospective outcomes studies are needed to evaluate the efficacy and safety of these combinations. SN - 1879-1913 UR - https://www.unboundmedicine.com/medline/citation/19084086/A_review_of_the_current_status_of_the_management_of_mixed_dyslipidemia_associated_with_diabetes_mellitus_and_metabolic_syndrome_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0002-9149(08)01661-5 DB - PRIME DP - Unbound Medicine ER -